Very Late Scaffold Thrombosis: Intracoronary Imaging and Histopathological and Spectroscopic Findings

Journal of the American College of Cardiology

Volumn 66, Issue 17, 2015, Pages 1901-1914

  Räber, Lorenz ^a   Brugaletta, Salvatore ^b   Yamaji, Kyohei ^a   O'Sullivan, Crochan J ^c   Otsuki, Shuji ^b   Koppara, Tobias ^d   Taniwaki, Masanori ^a   Onuma, Yoshinobu ^e   Freixa, Xavier ^b   Eberli, Franz R ^c   Serruys, Patrick W ^f   Joner, Michael ^d   Sabaté, Manel ^b   Windecker, Stephan ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BARCELONA   (Spain)

^c TRIEMLI HOSPITAL   (Switzerland)

^d CVPATH INSTITUTE   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

bioresorbable scaffold; coronary artery disease; optical coherence tomography; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL;

ADULT; AGED; ARTICLE; BIORESORBABLE SCAFFOLD; CARDIAC IMAGING; CASE REPORT; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; DISEASE SEVERITY; EOSINOPHIL COUNT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFRARED SPECTROSCOPY; LOW DRUG DOSE; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TERTIARY HEALTH CARE; THROMBOSIS; THROMBUS ASPIRATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VERY LATE SCAFFOLD THROMBOSIS; ADVERSE EFFECTS; FEMALE; TIME; TISSUE SCAFFOLD;

AGED; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; THROMBOSIS; TIME FACTORS; TISSUE SCAFFOLDS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84945971031     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.08.853     Document Type: Article

References (42)

1. S. Windecker, S. Stortecky, G.G. Stefanini, and et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis BMJ 348 2014 g3859
2. E. Kedhi, K.S. Joesoef, E. McFadden, and et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
3. L. Räber, M. Magro, G.G. Stefanini, and et al. Very late coronary stent thrombosis of a newer generation everolimus-eluting stent compared with early generation drug-eluting stents: a prospective cohort study Circulation 125 2012 1110 1121
4. G.G. Stefanini, B. Kalesan, P.W. Serruys, and et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
5. J.A. Ormiston, P.W. Serruys, E. Regar, and et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial Lancet 371 2008 899 907
6. P.W. Serruys, J.A. Ormiston, Y. Onuma, and et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet 373 2009 897 910
7. S. Brugaletta, J.H. Heo, H.M. Garcia-Garcia, and et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J 33 2012 1325 1333
8. P.W. Serruys, H.M. Garcia-Garcia, and Y. Onuma From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 33 2012 16 25b
9. Y. Onuma, and P.W. Serruys Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 123 2011 779 797
10. J.P. Oberhauser, S. Hossainy, and R.J. Rapoza Design principles and performance of bioresorbable polymeric vascular scaffolds EuroIntervention 5 Suppl F 2009 F15 F22
11. P.W. Serruys, B. Chevalier, D. Dudek, and et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 385 2015 43 54
12. S. Puricel, D. Arroyo, N. Corpataux, and et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds J Am Coll Cardiol 65 2015 791 801
13. T. Gori, E. Schulz, and T. Munzel Immediate, acute, and subacute thrombosis due to incomplete expansion of bioresorbable scaffolds J Am Coll Cardiol Intv 7 2014 1194 1195
14. V. Kocka, L. Lisa, P. Tousek, T. Budesinsky, and P. Widimsky ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases Eur Heart J 34 2013 2073
15. D. Fernandez-Rodriguez, S. Brugaletta, S. Otsuki, and M. Sabate Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent? EuroIntervention 10 2014 600
16. T. Sato, M. Abdel-Wahab, and G. Richardt Very late thrombosis observed on optical coherence tomography 22 months after the implantation of a polymer-based bioresorbable vascular scaffold Eur Heart J 36 2015 1273
17. A. Karanasos, R.J. van Geuns, F. Zijlstra, and E. Regar Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy Eur Heart J 35 2014 1781
18. L. Timmers, P.R. Stella, and P. Agostoni Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy Eur Heart J 36 2015 393
19. E.P. McFadden, E. Stabile, E. Regar, and et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy Lancet 364 2004 1519 1521
20. S. Windecker, and B. Meier Late coronary stent thrombosis Circulation 116 2007 1952 1965
21. C. Stettler, S. Wandel, S. Allemann, and et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 2007 937 948
22. J. Daemen, P. Wenaweser, K. Tsuchida, and et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
23. S. Cook, P. Wenaweser, M. Togni, and et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation Circulation 115 2007 2426 2434
24. S. Cook, E. Ladich, G. Nakazawa, and et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis Circulation 120 2009 391 399
25. S.J. Kang, C.W. Lee, H. Song, and et al. OCT analysis in patients with very late stent thrombosis J Am Coll Cardiol Img 6 2013 695 703
26. G. Guagliumi, V. Sirbu, G. Musumeci, and et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging J Am Coll Cardiol Intv 5 2012 12 20
27. G. Nakazawa, A.V. Finn, M. Vorpahl, E.R. Ladich, F.D. Kolodgie, and R. Virmani Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents J Am Coll Cardiol 57 2011 390 398
28. M. Joner, A.V. Finn, A. Farb, and et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
29. W. Wijns, P.G. Steg, L. Mauri, and et al. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial Eur Heart J 35 2014 2812 2820
30. G.G. Stefanini, R.A. Byrne, P.W. Serruys, and et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials Eur Heart J 33 2012 1214 1222
31. Y. Onuma, P.W. Serruys, L.E. Perkins, and et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial Circulation 122 2010 2288 2300
32. F. Otsuka, E. Pacheco, L.E. Perkins, and et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model Circ Cardiovasc Interv 7 2014 330 342
33. M. Vorpahl, M. Nakano, L.E. Perkins, and et al. Vascular healing and integration of a fully bioresorbable everolimus-eluting scaffold in a rabbit iliac arterial model EuroIntervention 10 2014 833 841
34. J.L. Koenig Spectroscopy of Polymers 2nd edition 1999 Elsevier New York, NY 77 205
35. H.L. Dauerman The magic of disappearing stents J Am Coll Cardiol 58 2011 1589 1591
36. S. Cook, P. Eshtehardi, B. Kalesan, and et al. Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantation Eur Heart J 33 2012 1334 1343
37. L. Räber, S. Baumgartner, H.M. Garcia-Garcia, and et al. Long-term vascular healing in response to sirolimus- and paclitaxel-eluting stents: an optical coherence tomography study J Am Coll Cardiol Intv 5 2012 946 957
38. M.D. Radu, L. Räber, B. Kalesan, and et al. Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study Eur Heart J 35 2013 795 807
39. Y. Onuma, P.W. Serruys, T. Muramatsu, and et al. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the Absorb everolimus-eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B trial J Am Coll Cardiol Intv 7 2014 1400 1411
40. A.V. Finn, M. Joner, G. Nakazawa, and et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441
41. G. Guagliumi, M.A. Costa, V. Sirbu, and et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Circulation 123 2011 274 281
42. A. Mattesini, G.G. Secco, G. Dall'Ara, and et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance J Am Coll Cardiol Intv 7 2014 741 750